US · Healthcare · Biotechnology
EPS came in at -1.32 against a street estimate of -1.26 — a miss of 4.8%.
Analysts rate Kymera Therapeutics Inc a strong buy (22 buy, 2 hold, 0 sell out of 24) with an average price target of $139.83.
CONFIDENT Kymera reported strong KT-579 first-in-human proof of mechanism, with deep IRF5 degradation, broad biomarker effects and placebo-like safety. KT-621 remains on track for an AD Phase IIb readout by year-end, while lupus development is planned for early 2027. Q3 FY26 Management highlighted the U.S. moderate-to-severe atopic dermatitis opportunity and broader autoimmune expansion potential, but gave no regional revenue guidance. Analysts focused on KT-579 dose selection, lupus biomarker translation, expansion beyond lupus and the upcoming KT-621 AD readout. Management emphasized proof of mechanism, broad pathway effects and planned timelines, while withholding some detailed trial specifics. 2026-10-29…
Full summary in the app.
| Fund | Stake |
|---|---|
| FMR Inc | 14.85% |
| Baker Bros Advisors LP | 10.41% |
| venBio Select Advisor LLC | 8.99% |
| T. Rowe Price Associates, Inc. | 8.55% |
| T. Rowe Price Investment Management,Inc. | 7.53% |
| BlackRock Inc | 6.66% |
| Bvf Inc | 4.66% |
| Wellington Management Company LLP | 4.42% |
| Document | Date |
|---|---|
| Quarterly report · Q3 2026 HEADLINE NUMBERS • Kymera Therapeutics is a clinical-stage biopharmaceutical company developing small-molecule medicines using targeted protein degra | 2026-10-29 |
| Results announced · Q4 2026 HEADLINE NUMBERS • Third-quarter 2026 net loss was $132.0 million, or $1.32 per share, compared with a net loss of $82.2 million, or $0.94 per share, | 2026-10-29 |
| Quarterly report · Q2 2026 KYMERA THERAPEUTICS, INC. — 10-Q SUMMARY FOR RETAIL INVESTORS Q2 2026 (Period Ended June 30, 2026) --- HEADLINE NUMBERS • Cash & Equivalents: $124. | 2026-08-05 |
| Results announced · Q3 2026 KYMERA THERAPEUTICS Q2 2026 FINANCIAL SUMMARY HEADLINE NUMBERS • Cash Position: $1.5 billion in cash, cash equivalents and investments as of June 30 | 2026-08-05 |
| Board / officer change · Q3 2026 KYMERA THERAPEUTICS, INC. - 8-K SUMMARY BUSINESS & SEGMENT HIGHLIGHTS • Chief Medical Officer (CMO) Jared Gollob, M.D. resigned effective July 27, 2 | 2026-07-27 |
| Reg FD disclosure · Q2 2026 KYMERA THERAPEUTICS, INC. — 8-K SUMMARY HEADLINE NUMBERS • Company: Kymera Therapeutics, Inc. (NASDAQ: KYMR), Delaware corporation • Filing Date: Ju | 2026-06-25 |
| Shareholder vote results · Q2 2026 KYMERA THERAPEUTICS, INC. – 8-K SUMMARY HEADLINE NUMBERS • Annual Meeting of Shareholders held June 24, 2026 • Company ticker: KYMR, trades on Nasda | 2026-06-24 |
| Quarterly report · Q1 2026 KYMERA THERAPEUTICS, INC. – Q1 2026 10-Q SUMMARY HEADLINE NUMBERS • Cash & Marketable Securities: $1,546 million total as of March 31, 2026 (cash $1 | 2026-04-30 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Kymera Therapeutics Inc — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.